A 10% weight loss in patients age 60 to 64 may be able to provide Medicare savings of $8 billion over 10 years and $35 billion over their lifetime, according to Kenneth E. Thorpe, PhD.
A 10% weight loss in patients age 60 to 64 may be able to provide Medicare savings of $8 billion over 10 years and $35 billion over their lifetime, according to Kenneth E. Thorpe, PhD. Thorpe is a professor and chair of health policy and management at the Emory Rollins School of Public Health. He also serves as executive director of the partnership to fight chronic diseases and as a consultant to biopharmaceutical company, VIVUS.
He says many of the government's current approaches to weight loss are not addressing obesity, which is responsible for the rising rates of diabetes, hypertension and dyslipdemia.
“Weight loss generates lower spending,” Thorpe says. “We spend 40% more on healthcare for obese people than for normal-weight people.”
He says if the Medicare program made evidence-based lifestyle modification programs-such as the YMCA’s Diabetes Prevention Program via UnitedHealthcare-available to everyone at age 60, it would generate $7 billion in savings over the next decade.
“The payers that don't have evidence-based workplace wellness programs are missing big opportunity,” he says. “We have a decade of data showing that it works.”
He is also hopeful about a range of investigational weight-loss drugs still pending FDA approval he says can help achieve a 10% to 15% reduction in weight.
Go back to the Managed Healthcare Executive eNews newsletter.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
Drug Discount Programs Poised to Change with New Tech, Pharma Execs Survey Finds
April 22nd 2024It is somewhat mind-boggling in 2024 that more than one-third of pharma organizations still rely on manual entry of data into Excel spreadsheets to track duplicate discounts that can cost millions of dollars a year in lost revenue
Read More